{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "Grohskopf_et_al.__2023_",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 1
  },
  "completeness_stats": {
    "existing_evidence": 0,
    "new_evidence_found": 1,
    "total_evidence": 1
  },
  "verified_evidence": [],
  "new_evidence": [
    {
      "id": "comp_1",
      "quote": "Children were randomized n a 2:1 ratio to receive either Flu cel vax Quad rival ent (0.5 mL/dose containing 15 \u00b5g HA per virus for all ages) or aicensed comparator egg based IIV4 (0.25 mL/dose containing 7.5 \u00b5g HA per virus for those aged 6 through 35 months and 0.5 mL/dose containing 15 \u00b5g HA per virus for those aged 36 through 47 months) (130).",
      "relevance_explanation": "This quote describes a pivotal trial in which Flu cel vax Quadrivalent was compared to a licensed comparator egg-based IIV4, but it does not mention Flublok or Fluarix. It does not support the claim about Flublok vs Fluarix, so it is not relevant.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "model_used": "gpt-4.1"
}